Aktionärsstruktur

Inhaber in %
Freefloat 1,00
Vanguard Group, Inc. (Subfiler) 0,08
The Vanguard Group, Inc. 0,08
State Street Corp. 0,06
SSgA Funds Management, Inc. 0,06
BlackRock Institutional Trust Co. NA 0,03
Vanguard Total Stock Market Index Fund 0,03
BlackRock Fund Advisors 0,02
Vanguard 500 Index Fund 0,02
Columbia Management Investment Advisers LLC 0,01
Geode Capital Management LLC 0,01
Wellington Management Co. LLP 0,01
State Farm Investment Management Corp. 0,01
T. Rowe Price Associates, Inc. (Investment Management) 0,01
Morgan Stanley Smith Barney LLC 0,01

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2014 2015 2016 2017 2018
Personal am Ende des Jahres 126.500 127.100 126.400 134.000 135.100
Umsatz pro Mitarbeiter in Mio. EUR 587.620.553.359.684,00 552.321.007.081.039,00 569.121.835.443.038,00 570.753.731.343.284,00 603.508.512.213.175,00

Bilanz (in Mio. EUR) - Aktiva

2014 2015 2016 2017 2018
Summe Umlaufvermögen 59.311 60.210 65.032 43.088 46.033
Summe Anlagevermögen 88.512 91.011 97.544 94.741 90.232
Summe Aktiva 131.119 133.411 141.208 157.303 152.954

Bilanz (in Mio. EUR) - Passiva

2014 2015 2016 2017 2018
Gesamtverschuldung/ -verbindlichkeiten 18.760 19.861 27.126 34.581 30.480
Summe Fremdkapital 61.367 62.261 70.790 97.143 93.202
Summe Eigenkapital 69.752 71.150 70.418 60.160 59.752
Summe Passiva 131.119 133.411 141.208 157.303 152.954

Adresse

One Johnson & Johnson Plaza, 08933 New Brunswick
Telefon 1.732.524.0400
Internet http://www.jnj.com

Management

A. Eugene Washington
Independent Director
Alex Gorsky
Chairman & Chief Executive Officer
Anne M. Mulcahy
Lead Independent Director
Charles O. Prince
Independent Director
Chris DelOrefice
Vice President-Investor Relations
Ciro Römer
Company Group Chairman
D. Scott Davis
Independent Director
Euan Stuart Thomson
Global Head-Digital Technology
Ian Edward Lamert Davis
Independent Director
Jason Valmore
Vice President-Corporate Internal Audit
Jennifer A. Doudna
Independent Director
Jennifer Taubert
EVP & Worldwide Chairman-Pharmaceuticals
Joaquin Duato
Vice Chairman-Executive Committee
Joseph J. Wolk
Chief Financial Officer & Executive Vice President
Lawrence M. Blatt
Global Therapeutic Area Head, Infectious Diseases
Lisa Romanko
Senior Director-Investor Relations
Liz Fowler
Vice President-Global Health Policy
Marillyn A. Hewson
Director
Mark B. McClellan
Independent Director
Mary C. Beckerle
Independent Director
Matthew Stuckley
Senior Finance Director
Michael H. Ullmann
Executive Vice President & General Counsel
Paulus Stoffels
Chief Scientific Officer
Peter M. Fasolo
Chief Human Resources Officer & Executive VP
Peter Shen
Global Head-Research & Development
Ronald A. Kapusta
Chief Accounting Officer & Controller
Ronald A. Williams
Independent Director
Sarah L. Colamarino
Vice President-Corporate Equity
Scott White
Company Group Chairman
Thomas J. Spellman
Secretary
William David Perez
Independent Director